These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 373951)

  • 1. Effective clinical trials investigators and adequate incentives.
    Stamler J
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):666-70. PubMed ID: 373951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Who will be effective as a clinical trials investigator and what are adequate incentives? Appendix 1: A proposed mechanism and set of criteria for the evaluation of the scientific contribution of individual investigators in collaborative studies, including large clinical trials.
    Stamler R
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):671-2. PubMed ID: 373952
    [No Abstract]   [Full Text] [Related]  

  • 3. Publications and promotions for the clinical investigator.
    Relman AS
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):673-6. PubMed ID: 373953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Good clinical practices. Point of view of the university hospital].
    Bader JP
    Rev Med Interne; 1986 Nov; Spec No():11-3. PubMed ID: 3809775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conflict-of-interest policies for investigators in clinical trials.
    Lo B; Wolf LE; Berkeley A
    N Engl J Med; 2000 Nov; 343(22):1616-20. PubMed ID: 11096170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Problems of university-based scientists associated with clinical trials.
    Remington RD
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):662-5. PubMed ID: 373950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of quality control in the Multiple Risk Factor Intervention Trial.
    Cooper GR
    Control Clin Trials; 1986 Sep; 7(3 Suppl):3pp prior to 1S. PubMed ID: 3802844
    [No Abstract]   [Full Text] [Related]  

  • 8. Racial disparities among clinical research investigators.
    Getz K; Faden L
    Am J Ther; 2008; 15(1):3-11. PubMed ID: 18223347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Communications: Should mechanisms be established for sharing among clinical trial investigators experiences in handling problems in design, execution, and analysis? Methodology: the case for improved communications.
    Meinert CL; Hawkins BS
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):754-7. PubMed ID: 373968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rating authors' contributions to collaborative research: the PICNIC survey of university departments of pediatrics. Pediatric Investigators' Collaborative Network on Infections in Canada.
    Davies HD; Langley JM; Speert DP
    CMAJ; 1996 Oct; 155(7):877-82. PubMed ID: 8837534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Communications: Should mechanisms be established for sharing among clinical trial investigators experiences in handling problems in design, execution, and analysis? Problems of omission in communications.
    Mosteller F
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):761-4. PubMed ID: 373970
    [No Abstract]   [Full Text] [Related]  

  • 12. Incentives for preventing smoking in children and adolescents.
    Johnston V; Liberato S; Thomas D
    Cochrane Database Syst Rev; 2012 Oct; 10():CD008645. PubMed ID: 23076949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of toxicity in cooperative oncology clinical trials: the long and short of it.
    Gwede CK; Johnson DJ; Daniels SS; Trotti A
    J Oncol Manag; 2002; 11(2):15-21. PubMed ID: 11989815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical research activity of the French cancer cooperative network: Overview and perspectives].
    Dubois C; Morin F; Moro-Sibilot D; Langlais A; Seitz JF; Girault C; Salles G; Haioun C; Deschaseaux P; Casassus P; Mathiot C; Pujade-Lauraine É; Votan B; Louvet C; Delpeut C; Bardet É; Vintonenko N; Hoang Xuan K; Vo M; Michon J; Milleron B
    Bull Cancer; 2017; 104(7-8):652-661. PubMed ID: 28688747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does communication between investigators improve the conduct of the multicentre study?
    Marley JE; Lal D; Snaith J
    Br J Clin Pract; 1989 May; 43(5):158-60. PubMed ID: 2590632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A framework for the quality assurance of clinical data.
    Williams OD
    Clin Pharmacol Ther; 1979 May; 25(5 Pt 2):700-2. PubMed ID: 373958
    [No Abstract]   [Full Text] [Related]  

  • 17. [Quality assurance of clinical trials].
    Alexandre JM; Abadie E
    Rev Med Interne; 1986 Nov; Spec No():7-10. PubMed ID: 3809782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Researchers' views of the acceptability of restrictive provisions in clinical trial agreements with industry sponsors.
    Mello MM; Clarridge BR; Studdert DM
    Account Res; 2005; 12(3):163-91. PubMed ID: 16634168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials profile: professionals and sites.
    Paschoale HS; Barbosa FR; Nita ME; Carrilho FJ; Ono-Nita SK
    Contemp Clin Trials; 2010 Sep; 31(5):438-42. PubMed ID: 20601160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of data audits in detecting scientific misconduct. Results of the FDA program.
    Shapiro MF; Charrow RP
    JAMA; 1989 May; 261(17):2505-11. PubMed ID: 2704109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.